GlassScriptPhysician profile
Donya M Woconish
NPI 1487778999
$1,643.26
in general payments reported to CMS, 2019-2025
23 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $662 · 2022: $327 · 2023: $236 · 2024: $195 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.22 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $377.79 | 2021-2024 | Trulance |
| Qol Medical, LLC | $114.32 | 2021-2024 | Sucraid |
| Janssen Biotech, INC. | $85.11 | 2021-2022 | |
| Gilead Sciences, INC. | $84.62 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $81.76 | 2021-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $57.66 | 2021-2024 | Gattex, Entyvio |
| Pfizer INC. | $50.37 | 2024-2025 | |
| Ardelyx, INC. | $49.83 | 2022-2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.76 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $44.17 | 2024-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $42.05 | 2025 | |
| Madrigal Pharmaceuticals | $32.85 | 2025 | Rezdiffra |
| Amgen INC. | $30.38 | 2021 | |
| Lilly USA, LLC | $21.51 | 2023 | Taltz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $21.46 | 2025 | Zenpep |
| Eisai INC. | $21.00 | 2023 | |
| Mallinckrodt Hospital Products INC. | $20.53 | 2023 | Acthar |
| Genentech USA, INC. | $20.38 | 2024 | Tecentriq, Avastin |
| Ferring Pharmaceuticals INC. | $16.80 | 2025 | Rebyota |
| Exelixis INC. | $15.00 | 2025 | Cabometyx |
| Integra Lifesciences Corporation | $14.31 | 2022 | |
| Ironwood Pharmaceuticals, INC | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donya Woconish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.